Acadia’s Daybue (trofinetide) | Phase III LAVENDAR (NCT04181723) | 187 patients | 12 weeks | Met co-primary endpoints of RSBQ and CGI-I |
---|---|---|---|---|
Anavex’s ANAVEX2-73 | Phase III AVATAR (NCT03941444) | 33 patients | 7 weeks | Met primary endpoint of RSBQ |
Anavex’s ANAVEX2-73 | Phase II/III EXCELLENCE (NCT04304482) | 92 patients | 12 weeks | Ongoing (primary endpoint of RSBQ) |